Physician profile
Gregory W Mattingley
NPI 1215933379
$4,712,274.32
in general payments reported to CMS, 2019-2025
58 companies · $1.0M in 2025
The $1.0M reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601K · 2020: $300K · 2021: $540K · 2022: $558K · 2023: $857K · 2024: $842K · 2025: $1.0M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.2M · Consulting Fee: $704K · Honoraria: $353K · Travel and Lodging: $334K · Food and Beverage: $46K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $39K · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,235,386.90 |
| Consulting Fee | $704,101.04 |
| Honoraria | $353,234.69 |
| Travel and Lodging | $333,675.30 |
| Food and Beverage | $46,302.91 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $39,175.00 |
| Education | $149.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $713,086.79 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $516,066.14 | 2022-2025 | Auvelity, Sunosi |
| Abbvie INC. | $474,277.75 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $447,617.14 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $424,024.02 | 2019-2025 | Ingrezza |
| H. Lundbeck A S | $411,366.31 | 2019-2025 | Brintellix, Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $322,881.31 | 2019-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $203,107.35 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $150,865.20 | 2019-2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $141,504.71 | 2024-2025 | Cobenfy |
| Allergan, INC. | $106,625.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $82,046.18 | 2019-2025 | Trintellix |
| Noven Pharmaceuticals, INC. | $77,091.63 | 2020-2025 | Xelstrym |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $76,682.60 | 2019-2025 | Rejoyn, Rexulti |
| Ironshore Pharmaceuticals INC. | $73,314.92 | 2019-2024 | Jornay Pm |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $66,296.79 | 2020-2022 | |
| Corium, LLC | $53,019.99 | 2021-2025 | Azstarys, Azstarys |
| Vanda Pharmaceuticals INC. | $43,129.28 | 2019-2025 | Fanapt |
| Biogen, INC. | $39,162.83 | 2022-2024 | Zurzuvae, Skyclarys, Spinraza |
| Teva Pharmaceuticals USA, INC. | $36,182.75 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka Pharmaceutical Co., Ltd. | $30,387.94 | 2020 | |
| Shire North American Group INC | $28,863.67 | 2019 | |
| Tris Pharma INC | $21,917.30 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Sunovion Pharmaceuticals INC. | $20,702.38 | 2019-2022 | |
| Adlon Therapeutics L.P. | $20,301.89 | 2019-2021 | |
| Takeda Pharmaceutical Company, Limited | $19,675.32 | 2020-2021 | |
| Boehringer Ingelheim International Gmbh | $17,393.60 | 2024-2025 | |
| Eli Lilly and Company | $13,425.00 | 2025 | |
| Sage Therapeutics, LLC | $12,933.70 | 2020-2025 | Zurzuvae |
| Acadia Pharmaceuticals INC | $11,475.86 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $9,280.00 | 2023 | |
| Janssen Global Services, LLC | $7,639.68 | 2023-2025 | Spravato |
| Livanova USA, INC. | $6,983.16 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Collegium Pharmaceutical, INC. | $5,682.82 | 2025 | Jornay Pm |
| Janssen Scientific Affairs, LLC | $5,140.35 | 2024 | |
| Luye Pharma (USA) Ltd. | $4,663.55 | 2025 | Erzofri Extended-Release |
| Genentech, INC. | $4,177.91 | 2019 | |
| Noven Therapeutics, LLC | $4,121.47 | 2020-2025 | Xelstrym, Secuado |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,115.00 | 2023-2024 | |
| Alfasigma USA, INC. | $2,792.50 | 2020 | |
| Lundbeck LLC | $2,076.03 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $300.46 | 2019-2025 | Aplenzin |
| Neos Therapeutics, Lp | $252.67 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Rhodes Pharmaceuticals L.P. | $187.88 | 2019 | |
| Almatica Pharma LLC | $115.46 | 2023-2025 | Loreev Xr |
| Indivior INC. | $68.71 | 2019-2023 | Perseris |
| Jazz Pharmaceuticals INC. | $66.67 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $51.79 | 2019 | |
| Avanir Pharmaceuticals, INC. | $42.03 | 2019 | |
| Validus Pharmaceuticals LLC | $30.96 | 2019 | |
| Amgen INC. | $17.19 | 2019 | |
| Neuronetics, INC. | $15.73 | 2019 | |
| Aytu Biopharma, INC. | $13.69 | 2021 | |
| Merck Sharp & Dohme LLC | $13.02 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mattingley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.